Patients treated with Odactra experienced a 22% reduction in total combined rhinitis score compared with placebo. The expanded approval was supported by data from a phase 3 trial (ClinicalTrials ...

12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax, ALK-Abello) is indicated 'in adult patients (18-65 years) diagnosed by clinical history and a positive test of house ...

The U.S. Food and Drug Administration has expanded its indication of Odactra, a house dust mite allergen tablet, for the ...

ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA ® tablet for use in young children with house dust mite (HDM) allergy.

12 SQ-HDM SLIT (standard quality house dust mite sublingual lyophilisate; Acarizax) is available on the NHS as a possible treatment for moderate to severe house dust mite allergic rhinitis in people ...

The U.S. Food and Drug Administration has expanded its indication of ALK's Odactra, a house dust mite allergen tablet, for the treatment of house dust mite-induced allergic rhinitis, with or ...

a house dust mite allergen tablet, for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, to include children ages 5 through 11 years. Odactra is an ...

ALK ( ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s ACARIZAX ® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX ® is now ...

WEDNESDAY, March 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has expanded its indication of Odactra, a house dust mite allergen tablet, for the treatment of house dust mite ...

From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, March 5, 2025 (HealthDay News) -- The U.S. Food and Drug ...